Supplemental Table 1: Demographics of COVID-19 patients, with and without HAI

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|   | **No MRSA** | **MRSA** | **P** | **No CLABSI\*** | **CLABSI** | **P** |
| N | 320767 | 326 |   | 71967 | 628 |   |
| Age > 65 | 49.3% (158090) | 43.9% (143) | P=0.05 | 52.9% (38045) | 41.2% (259) | P<0.001 |
| Sex: Male | 50.6% (162444) | 57.7% (188) | P=0.011 | 51.3% (36889) | 61.8% (388) | P<0.001 |
| Race/Ethnicity |  |  | P=0.13 |  |  | P<0.001 |
| Black/African American | 16.7% (53223) | 12.9% (41) |   | 17.6% (12645) | 14.9% (93) |   |
| Hispanic/Latino | 22.0% (70270) | 24.6% (78) |   | 21.5% (15461) | 34.3% (215) |   |
| Other/Unknown | 7.1% (22529) | 9.1% (29) |   | 7.7% (5530) | 11.0% (69) |   |
| White | 54.3% (173281) | 53.3% (169) |   | 53.3% (38314) | 39.8% (249) |   |
| Elixhauser Comorbidity Score | 6.00 [0.00, 13.00] 8.07+/- 9.08 | 14.00 [7.25, 22.00] 15.09+/-10.22 | P<0.001 | 12.0 [5.0, 19.0] 12.8+/-10.2 | 14.0 [7.0, 22.0] 15.6+/-11.0 |   |
| ICU within 3 days of admission | 23.0% (73627) | 46.3% (151) | P<0.001 | 48.7% (35080) | 62.9% (395) | P<0.001 |
| Vent within 3 days of admission | 5.8% (18694) | 22.4% (73) | P<0.001 | 20.9% (15070) | 37.9% (238) | P<0.001 |
| Length of Stay (days, before HAI) | 5.00 [3.00, 10.00] 7.91+/-10.61 | 14.00 [9.00, 23.00] 18.32+/-20.24 | P<0.001 | 11.0 [6.0, 20.0] 15.1+/-15.6 | 16.0 [10.0, 26.0] 20.2+/-15.3 | P<0.001 |
| Toci/Bari (before HAI) |  5.7% (18428) |  18.1% (59) |  P<0.001 | 12.4% (8922) | 24.5% (154) | P<0.001 |
| Dexamethasone (before HAI) |  |  | P<0.001 |  |  | P<0.001 |
| None | 41.8% (134238) | 21.2% (69) |   | 36.0% (25924) | 25.6% (161) |   |
| ≤ 6 mg | 34.3% (110161) | 36.5% (119) |   | 33.8% (24353) | 31.8% (200) |   |
| > 6 mg | 23.8% (76368) | 42.3% (138) |   | 30.1% (21690) | 42.5% (267) |   |
| Any High Dose Steroids (before HAI) | 38.3% (122995) | 72.4% (236) | P<0.001 | 52.9% (38092) | 77.9% (489) | P<0.001 |

\*Includes only those patients with central line